Sulodexide

Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%) . Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA) . Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease[1]. Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.

Product Specifications

CAS Number

[57821-29-1]

UNSPSC

12352100

Target

Thrombin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sulodexide.html

Purity

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : < 1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

[Sulodexide]

References & Citations

[1]Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012 Apr 1;12 (2) :73-81. |[2]Yung S, et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy[J]. PloS one, 2013, 8 (1) : e54501.|[3]Jo H, et al. Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy[J]. BMB reports, 2014, 47 (11) : 637.|[4]Huang R, et al. Sulodexide attenuates liver fibrosis in mice by restoration of differentiated liver sinusoidal endothelial cell[J]. Biomedicine & Pharmacotherapy, 2023, 160: 114396.|[5]Ying J, et al. Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis[J]. Frontiers in immunology, 2023, 14: 1172892.